blockonomi.com / Page 7

As volatility and market fatigue continue to challenge retail crypto traders, IODeFi is positioning itself as an alternative approach to digital asset participation--one that prioritizes automation, infrastructure, and system-driven execution over .. ...

Following its massive reorganization of 600 million tokens, Ripple has transferred over $152 million worth of XRP to Binance wallets, sparking renewed market attention. On December 12th, according to Whale Alert, 75,316,328 XRP were transferred from ...

As romance scams cost crypto holders above $5B in 2024, the best crypto to invest in is DeepSnitch AI, shipping tools for dicey markets with 100x potential and an imminent launch.

Bitcoin has lost the key $90,000 level after a roller-coaster reaction to December's Fed rate cut. The Fed's quarter-point rate reduction initially sparked optimism across all markets, but what looked like safe altcoins to buy quickly whipsawed due . ...

Finding the best crypto presale is how many investors position themselves before the biggest market moves happen. While established cryptocurrencies dominate headlines after rallies begin, the real upside often comes earlier, during presales, when .. ...

When Bitcoin pulls back or Ethereum stalls at resistance, capital rarely sits idle. It moves. That rotation is happening again. As major assets hesitate and meme coins lose momentum, attention is shifting quickly toward a smaller DeFi altcoin that .. ...

Visa launches USDC stablecoin settlement in the U.S., enabling banks to settle via blockchain with 7-day access and faster operations.

Best stocks to buy: Microsoft, Amazon, Nvidia, Apple, and Alphabet earn strong Wall Street analyst Buy ratings based on growth prospects and cash flow strength.

Paxful announces agreements with the United States Department of Justice (DOJ) and the Financial Crimes Enforcement Network (FinCEN) to resolve longstanding investigations concerning historic conduct prior to 2023, during the tenure of former Paxful ...

Pfizer (PFE) stock climbs despite weaker 2026 profit forecast and declining COVID-19 vaccine sales expectations from the pharmaceutical company.